| [1] |
Giordano SH, Temin S, Kirshner JJ, et al. Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline[J]. J Clin Oncol,2014,32(19):2078-2099.
|
| [2] |
Ramakrishna N, Temin S, Chandarlapaty S, et al.Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: American Society of Clinical Oncology clinical practice guideline[J]. J Clin Oncol,2014,32(19):2100-2108.
|
| [3] |
Lin NU, Bellon JR, Winer EP. CNS metastases in breast cancer[J]. J Clin Oncol,2004,22(17):3608-3617.
|
| [4] |
Brufsky AM, Mayer M, Rugo HS, et al. Central nervous system metastases in patients with HER2-positive metastatic breast cancer: Incidence, treatment, and survival in patients from registHER [J]. Clin Cancer Res, 2011,17 (14):4834-4843.
|
| [5] |
Olson EM, Najita JS, Sohl J, et al. Clinical outcomes and treatment practice patterns of patients with HER2-positive metastatic breast cancer in the post-trastuzumab era [J].Breast,2013,22(4):525-531.
|
| [6] |
Pestalozzi BC, Holmes E, de Azambuja E, et al. CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01) [J]. Lancet Oncol,2013,14(3):244-248.
|
| [7] |
Hess KR, Esteva FJ. Effect of HER2 status on distant recurrence in early stage breast cancer[J]. Breast Cancer Res Treat,2013,137(2):449-455.
|
| [8] |
Pestalozzi BC, Francis P, Quinaux E, et al. Is risk of central nervous system (CNS) relapse related to adjuvant taxane treatment in node-positive breast cancer? Results of the CNS substudy in the intergroup Phase III BIG 02-98 Trial[J]. Ann Oncol,2008,19(11):1837-1841.
|
| [9] |
Gori S, Rimondini S, De Angelis V, et al. Central nervous system metastases in HER-2 positive metastatic breast cancer patients treated with trastuzumab:incidence,survival,and risk factors[J]. Oncologist,2007,12(7):766-773.
|
| [10] |
Park YH, Park MJ, Ji SH, et al. Trastuzumab treatment improves brain metastasis outcomes through control and durable prolongation of systemic extracranial disease in HER2-overexpressing breast cancer patients[J]. Br J Cancer,2009,100(6):894-900.
|
| [11] |
Sperduto PW, Kased N, Roberge D, et al. Effect of tumor subtype on survival and the graded prognostic assessment for patients with breast cancer and brain metastases[J]. Int J Radiat Oncol Biol Phys,2012,82(5):2111-2117.
|
| [12] |
Bendell JC, Domchek SM, Burstein HJ, et al. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma[J]. Cancer, 2003,97(12):2972-2977.
|